EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden
Crossref DOI link: https://doi.org/10.1186/s13075-016-0950-0
Published Online: 2016-02-19
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gülfe, Anders
Wallman, Johan K.
Kristensen, Lars Erik